167 related articles for article (PubMed ID: 25266814)
1. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis.
Lin I; Muser E; Munsell M; Benson C; Menzin J
J Med Econ; 2015 Mar; 18(3):219-29. PubMed ID: 25266814
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
4. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
6. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis.
Lin L; Zhao YJ; Zhou HJ; Khoo AL; Teng M; Soh LB; Lim BP; Sim K
Int Clin Psychopharmacol; 2016 Mar; 31(2):84-92. PubMed ID: 26619182
[TBL] [Abstract][Full Text] [Related]
7. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
[TBL] [Abstract][Full Text] [Related]
10. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
14. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Ball DE; Kinon BJ
BMC Psychiatry; 2010 Jan; 10():11. PubMed ID: 20109170
[TBL] [Abstract][Full Text] [Related]
15. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
Lafeuille MH; Gravel J; Lefebvre P; Fastenau J; Muser E; Doshi D; Duh MS
J Med Econ; 2013 Nov; 16(11):1290-9. PubMed ID: 24006903
[TBL] [Abstract][Full Text] [Related]
17. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
18. Forensic assertive community treatment: preventing incarceration of adults with severe mental illness.
Lamberti JS; Weisman R; Faden DI
Psychiatr Serv; 2004 Nov; 55(11):1285-93. PubMed ID: 15534018
[TBL] [Abstract][Full Text] [Related]
19. Cost of relapse in schizophrenia.
Weiden PJ; Olfson M
Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
[TBL] [Abstract][Full Text] [Related]
20. The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework.
Martins R; Kadakia A; Williams GR; Milanovic S; Connolly MP
J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37555674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
